The main theme of the report is the evolution and expansion of the innovation ecosystem in life sciences despite geopolitical, technological, and social uncertainties.
The report assesses trends in R&D funding, clinical trial activity, and the approval and launch of new drugs. It also analyzes the efficiency and productivity of clinical development using the updated Clinical Program Productivity Index and provides insights into the factors and conditions contributing to these processes. Special attention is given to operationally addressable components of clinical trial cycle times and the significance of new biopharmaceutical companies.